Objective To investigate the association of progesterone receptor (PGR) gene variants with susceptibility to recurrent pregnancy loss (RPL).
Introduction
Recurrent pregnancy loss (RPL), defined as three or more consecutive pregnancy losses before 24 weeks of gestation with the same partner, 1 is a major pregnancy complication affecting 1-3% of women of childbearing age. 2 RPL is multifactorial, and various factors were implicated in its pathogenesis. These include uterine anatomic abnormalities, chromosomal anomalies, thrombophilia and antiphospholipid syndrome, and immune disorders, 3 along with lifestyle factors and maternal infections. Polymorphic variants of cytokine, inflammatory, 4 coagulation factor, 5 and sex hormone receptor genes were described as risk factors for RPL. [6] [7] [8] [9] Despite the identification of several modifiable and non-modifiable risk factors, the exact causes underlying RPL remain unexplained in up to 50% of cases. 10 Progesterone is a 21-carbon steroid hormone, produced in the ovaries, brain, placenta, and adrenal glands, and plays a central role in maintaining pregnancy in early gestation, and in controlling ovulation and mammary gland development. 11 Several observational studies have suggested a role for progesterone in RPL development, as reduced progesterone in early pregnancy is linked with a heightened risk of RPL, [3] [4] [5] [6] [7] [8] [9] and progesterone treatment was claimed to be useful in preventing miscarriages. 12 Progesterone acts by binding its cytosolic progesterone receptor (PR), a member of the steroid and thyroid superfamily, which exists as PRA and PRB isoforms, both of which are transcribed from the same gene. 13 The gene encoding human PR (PGR) is located on chromosome 11q22-23, and consists of eight exons.
14 The hPR-A and hPR-B subtypes differ structurally in their N-terminal domain, which is shorter by 164 amino acids in PR-A compared with PR-B, and functionally, as PR-A is necessary for optimal uterine physiology and reproduction, whereas PR-B, which is active throughout gestation, assists in the maintenance of uterine quiescence. 15 The PR gene (PGR) is highly polymorphic, 16 and several polymorphic variants in the PGR gene have been associated with reproductive problems, 13, [16] [17] [18] including RPL. [6] [7] [8] A few studies have investigated the association of genetic variants in PGR with RPL, often with inconclusive findings. Most of these studies have dealt with PROGINS insertion variant, and few have studied other single nucleotide polymorphisms (SNPs). PGR variant rs1042838 (1978G>T; L660V) was associated with RPL in German and Taiwanese women, 8, 9 but not in Brazilian, 19 Austrian, 7 or Indian women. 6 Furthermore, PGR polymorphic variants were implicated in implantation failure according to some studies, 20 but not in other studies. 21 In view of the importance of sex hormone receptor signalling in pregnancy, this study investigated genetic variations in the progesterone pathway, and their association with RPL.
Methods

Subjects
This was a retrospective case-control study, performed at the outpatient obstetrics and gynaecology (OB/GYN) service of Frahat Hached Hospital (Sousse, Tunisia) and Fattouma Bourguiba Hospital (Monastir, Tunisia). Between January 2014 and April 2016, 396 unrelated women with RPL (mean age 32.4 AE 6.3 years), defined as having three or more consecutive miscarriages of unknown aetiology with the same partner, that occurred during the first trimester of gestation were recruited. All RPL cases included had their first pregnancy between 19 and 34 years of age, and had three or more pregnancy losses prior to entry into the study. RPL was assessed in accordance with Royal College of Obstetricians and Gynaecologists (RCOG) guidelines, which are consistent with the American College of Obstetricians and Gynecologists (ACOG) guidelines. 1 These included testing for anti-phospholipid antibodies, karyotyping of both partners, pelvic ultrasound scan for anatomical uterine evaluation, and screening for inherited thrombophilia (factor V Leiden and factor II G20210A), for all cases. Subjects who tested positive for any of these procedures were excluded from participation.
Exclusion criteria included older age (>40 years) at first pregnancy, Rh blood group incompatibility, previous history of pre-eclampsia (elevation in systolic/diastolic blood pressure of >145/95 mmHg, or rise in systolic/diastolic blood pressure of >30/15 mmHg on two or more occasions), preclinical miscarriages, and/or biochemical pregnancy. Additional exclusion criteria included systemic autoimmunity, diabetes mellitus, thyroid and liver dysfunction, anatomical disorders, and infections. As a result of cultural and religious concerns, karyotyping of the products of conception was not routinely performed.
Controls comprised 361 unrelated multiparous university and hospital employees or volunteer women (mean age 36.1 AE 7.9 years) with two or more successful natural pregnancies, not conceived through assisted reproduction techniques, with no spontaneous miscarriages, and with no immediate family history of miscarriage. Controls were also excluded if they reported past induced terminations of pregnancy (TOPs), hypertension, intrauterine infection, uterine rupture, obstetric bleeding, and malignancy, all of which were modified by specific PGR genotype. Successful pregnancy was defined as live full-term birth (no preterm births). Controls were recruited following a routine checkup following an uncomplicated pregnancy, and were matched to cases according to self-declared ethnic origin. All participants had self-reported normo-ovulatory cycles, and were asked to sign a consent form prior to inclusion in the study; only those with signed consent were included in the study. Blood samples were taken from all participants in a tube containing ethylenediaminetetraacetic acid (EDTA) for total genomic DNA extraction. 
PGR genotyping
We identified eight SNPs in the PGR gene with a minor allele frequency (MAF) of ≥5%, previously reported to be of clinical relevance, using ENTREZ GENE SNP GENEVIEW (National Center for Biotechnology Information, NCBI, Bethesda, MD, USA). The variants selected were rs578029 (intron 4), rs1042838/V660L (exon 4), rs3740753/S180T (exon 8), rs10895068 (5 0 untranslated region, 5 0 -UTR), rs608995 (3 0 -UTR), and rs1942836 (intergenic/unknown), along with the haplotype-tagging SNPs (htSNPs) rs471767 (3'-UTR) and rs590688 (intron 6). PGR genotyping was performed by the VIC-and FAM-labelled allelic discrimination method, using assay-on-demand TaqMan assays, which were ordered from Applied Biosystems (Foster City, CA, USA). The reaction was performed in a 6-ll volume on a StepOne Plus real-time polymerase chain reaction (PCR) system, according to the manufacturer's instructions (Applied Biosystems). Replicate blinded quality control samples were included to assess the reproducibility of the genotyping procedure; concordance was >99%.
Statistical analysis
Statistical analysis was performed using SPSS 23 (IBM, Armonk, NY, USA). Continuous variables were presented as means (AESDs), whereas categorical variables were expressed as a percentage of the total. Differences in means were assessed by Student's t-test, and Pearson's v 2 test was used for differences in proportions. The Hardy-Weinberg equilibrium (HWE) was evaluated in HAPLOVIEW (www.broad.mit.edu/ mpg/haploview). The calculation of the power for detecting an association between PGR variants and RPL was performed with the GENETIC POWER CALCULATOR (pngu.mgh.harvard.edu/ purcell/cgi-bin/cc2k.cgi). The parameters used were number of cases and control subjects, genotypic relative risk for heterozygote (1/2) and homozygous minor allele (2/2), and MAF for RPL cases and controls for the eight tested SNPs, and assuming a 3.0% prevalence of RPL in the population. Assuming these parameters, we calculated the overall power (86.7%) as the average power of the tested SNPs.
All logistic analyses were performed with the number of copies of the minor (variant) allele as the predictor. HAPLO-VIEW was used to check linkage disequilibrium (LD) between SNPs, beside their haplotype patterns. Despite phase ambiguity, PGR haplotypes were modelled based on data snooping using the expectation maximisation algorithm for maximising the likelihood in HAPLOVIEW 4.2, which creates highly accurate population frequency estimates of phased haplotypes based on the maximum likelihood as determined from the unphased input (www.broad.mit.edu/mpg/haploview), followed by likelihood ratio testing. Of the 16 possible haplotypes only seven were found to be common (with a frequency of >2%), and were included in further analysis. Taking the control group as the reference, logistic regression analysis was used for determining odds ratios (ORs) and 95% confidence intervals (95% CIs) associated with RPL risk using SNPSTATS (bioinfo.iconcologia.net/SNPstats). Statistical significance was set at P < 0.05.
Results
Study subjects
The demographic and clinical characteristics of study participants are presented in Table S1 . A total of 429 RPL cases and 383 control subjects were initially included. Of these, 33 (7.7%) cases and 22 controls (5.7%) were excluded because of technical problems relating to sample collection, sample volume, or incomplete data collection. This left 396 RPL cases and 361 controls for analysis. The prevalence of smoking (P = 0.69), fasting glucose (P = 0.55), previous oral contraceptive use (P = 0.51), and ethnic origin (P = 0.09) were comparable between RPL cases and controls. On the other hand, significant differences between RPL cases and controls were noted in the mean age at inclusion of study (P < 0.001), body mass index (BMI; P = 0.003), and menarche (P < 0.001). Although 1/3 controls were >40 years of age at inclusion in the study, 1/7 RPL cases were >40 years of age, and all RPL cases had their first pregnancy between 19 and 34 years of age. Accordingly, age and BMI were selected as covariates to be controlled for in subsequent analysis.
Association studies
The genotype distributions of the tested PGR variants were in HWE among study subjects ( Table 1 ). The risk of disease for the variant allele is then addressed at two levels. First, the minor allele frequency (MAF), defined as the frequency at which the second most common allele occurs in a given population, is calculated as it differentiates between common and rare variants in the population. Second, the distribution of the minor allele among participants is examined: i.e. major/major, major/minor, or minor/minor. The MAF of the tested PGR SNPs in women with RPL and in control women are presented in Table 1 . Of the PGR SNPs analysed, higher MAFs of rs590688 (P < 0.001, OR 1.46, 95% CI 1.19-1.80), rs10895068 (P = 0.005, OR 2.63, 95% CI 1.31-5.28), and rs1942836 (P < 0.001, OR 1.69, 95% CI 1.32-2.14) were seen in RPL cases, compared with controls. Corrected P values for multiple-comparisons analysis (P c ) confirmed the association of rs590688 (P c = 1.6 9 10 -3 ), rs10895068 (P c = 0.04), and rs1942836 (P c = 1.5 9 10 À4 ) with an increased risk of
RPL.
The distribution of PGR genotypes in women with RPL and control women are summarised in Table 2 . Significantly higher frequencies of heterozygous (1/2) rs608995 (46.7 versus 36.0%; P = 0.011), along with heterozygous (1/2) and homozygous (2/2) rs590688 (P = 0.002), rs10895068 (P = 0.023), and rs1942836 (P = 1.5 9 10 À4 ) genotype carriers were seen between RPL cases versus control women, respectively. The risk of RPL associated with a specific PGR genotype was further confirmed by testing the effect of age and BMI as confounding factors. Results from Table 3 confirmed the association of rs590688 (P a = 0.021), rs10895068 (P a = 0.047), rs608995 (P a = 0.010), and rs1942836 (P a = 4.2 9 10 À3 ) with RPL, after controlling for age, BMI, and menarche, and established a 'dose-dependent' effect associated with both rs590688 and rs1942836. In contrast, the association of both rs608995 (adjusted OR, aOR 1.44, 95% CI 1.08-1.92) and rs1042839 (aOR 1.50, 95% CI 1.06-2.13) was seen only in heterozygous carriers (Table 3) .
Haploview analysis
Linkage disequilibrium (LD) varied among the PGR variants associated with RPL: rs590688, rs10895068, rs608995, and rs1942836 ( Figure S1 ). Diversity in haplotype assignment was seen, with the common haplotype (>2% of total) seen in seven of the theoretical 16 identified haplotypes, which captured 95.8% of all haplotypes. An increased frequency of CGTC and a reduced frequency of GGAT haplotypes was noted in women with RPL, compared with control women, thereby assigning an RPL-susceptible and RPL-protective nature to these haplotypes, respectively (Table 4) . It should be noted that haplotype analysis was based on data snooping, and thus is presented as exploratory, pending confirmation. This association remained significant after controlling for multiple comparisons and adjusting for covariates.
Discussion
Mounting evidence implicates altered expression and/or activity of progesterone receptors with RPL pathogenesis. 22 In view of the role that progesterone receptor signalling plays in female reproduction, 12 we investigated the association of PGR gene variants and RPL. Although many genetic variants of the PGR gene have been reported recently, the HWE, Hardy-Weinberg equilibrium. *P c , corrected P value, determined as P c = 1 -(1 -P) n , where n is the number of comparisons. novel finding here was the strong association of three of the eight tested variants (rs590688, rs10895068, and rs1942836) with RPL. Compared with previous studies on the topic, this study is distinct in the large sample size and the new SNPs investigated, and thus extends the list of variants in the PGR gene implicated in RPL pathogenesis, further supporting a key role for progesterone receptor signalling in pregnancy.
Main findings
The minor allele frequencies of the eight tested PGR variants among control subjects reflected the origin of the present-day Tunisian population, which is an admixture of different ethnic groups who invaded and populated Tunisia throughout history. These included Iberomarusians, Capsians, Phoenicians, Romans, Vandals, Byzantines, and Arabs, followed by massive Bedouin immigration in the 11th century. 23 The MAFs of rs471767, rs590688, and rs608995 were comparable between Tunisian, African, and white women (HapMap-CEU), whereas the MAFs of rs578029 and rs1942836 were between that of Tunisian and white women, but were lower than the rates established for African women. Whereas the minor allele of rs1042838 (3.94%) and rs3740753 (0.06%) was rare in African women, it was more frequent in Tunisian (12 and 21.43%) and European/white women (15 and 21.16%). This highlights the need for evaluation of the ethnic differences in genetic association studies.
Strengths and limitations
Our study has strengths, namely that it was sufficiently powered, that cases and controls were ethnically matched, hence minimising the problems of differences in genetic Haplotype association P < 0.001. *Haplotype frequency. **The most frequent haplotype in control women (GGAT) was taken as the reference (OR = 1.00); further OR calculations were made based on comparing haplotype frequencies against that of the GGAT haplotype. background, and that key covariates were controlled for in single SNP and haplotype analysis; however, there are several limitations to the study. The genotype-phenotype association was not fully addressed, which is important in defining the underlying mechanism. The retrospective case-control study design is also a limiting factor in addressing the causeeffect relationship. In addition, matching for ethnicity was based on self-declared Arab versus non-Arab Tunisian origin, thereby calling into question the adequacy in controlling for genetic population stratification bias. Lastly, the study examined the association of eight PGR candidate variants with RPL, thus prompting the speculation of the presence of additional PGR variants that influence RPL risk.
Interpretation
Previous studies on the association of PGR variants with RPL focused on PROGINS, a complex of 306-bp Alu elements (intron 7), which is in complete LD with rs1042838/V660L missense SNP (exon 4) and synonymous (His770His) variant (exon 5). 7,18 PROGINS variants were described as genetic risk factors for progesterone-dependent cancers, 13 and for pregnancy complications. 6, 9 The lack of association of rs1042838/V660L with altered RPL risk among Tunisians was in agreement with Australian, 7 Brazilian, 19 German, 24 and Indian studies, 6 but in apparent disagreement with a Taiwanese study. 9 This discrepancy is likely attributed to differences in sample size, selection criteria of study participants, or the ethnic background, including differences in the allele and genotype frequencies of rs1042838 (V660L) and LD structure among different ethnic groups.
The main finding here was the strong association of rs590688, rs10895068, and rs1942836 with increased risk of RPL. Although none of these variants were previously tested for their possible association with adverse pregnancy complications, including RPL, a few studies reported on their association with female reproductive cancers, including breast cancer, ovarian cancer, and endometrial cancer, 25, 26 often with inconclusive results. For example, a multi-centre study and a meta-analysis reported on the association of rs10895068 (+331G/A) with a heightened risk of breast cancer, presumably through the upregulation of the expression of the hPR-B isoform. 13, 27 The finding reported in an earlier meta analysis, and an Australian study did not support an association between rs10895068 with altered risk of breast cancer, however. 28, 29 Ethnic background, and study selection and inclusion appear to influence this association, suggesting that this SNP may not be directly causal.
hPR-B acts as an activator of the transcription progesterone-responsive gene process, whereas hPR-A is as an inhibitor for this function. Therefore, PGR variants are likely to influence the risk of RPL development by reducing the response to progesterone, partly by altering PR mRNA stability and PR expression. 30 This could be the basis for an effect of rs10895068 (+331G/A), found in the promoter region of the PGR gene, and is associated with increased PR-B production, in part by introducing an additional TATA box, thus altering the PR-A/PR-B ratio. 17 It also applies to rs194836, found in the PGR regulatory domain, and suggested to be involved in altered expression of PGR isoforms. 16 Collectively, our findings underscore the contribution of altered PR isoform expression to RPL pathogenesis.
Conclusion
In conclusion, our study is the first report to demonstrate that PGR rs590688, rs10895068, and rs1942836, but not the commonly studied rs1042838, are associated with RPL. Follow-up studies on additional PGR variants, and populations of related and distant ethnic origin, are needed to fully elucidate the association of PGR variants with the risk of RPL.
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